drugset / Trial / NCT01426958
Investigation of Ritonavir Effects on Afatinib Exposure in Healthy Subjects
RandomizedCrossoverOpen-labelTreatment
Summary
To study the effect of the P-glycoprotein inhibitor ritonavir on the pharmacokinetics (PK) of afatinib depending on the timepoint of ritonavir administration
Timeline
- Start
- 2011-08
- Primary completion
- 2011-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 40 mg | Oral |
| Subject | Ritonavir | Other / unclassified | — | Oral |
Indications
No indication recorded.